Lab Supplier Concentration 

1. Introduction

Lab supplier concentration refers to a market situation in which a small number of firms account for a substantial proportion of the supply of laboratory products, equipment, consumables, reagents, diagnostic products, analytical instruments, or related services.

Concentration by itself is not unlawful. Competition law becomes concerned when concentration:

• results from an anticompetitive merger or acquisition;
• enables a supplier to acquire or maintain dominance;
• facilitates coordinated conduct between suppliers;
• permits exclusion of competing suppliers;
• creates excessive dependence on one supplier;
• permits tying or bundling of equipment and consumables;
• restricts interoperability or access to essential inputs;
• uses exclusivity to foreclose rival distributors; or
• raises significant barriers to entry or switching.

Laboratory markets can be particularly susceptible because laboratories may make substantial investments in particular instruments, validated methods, proprietary reagents, software, maintenance arrangements and technical training. This can make switching suppliers costly.

2. Meaning of Supplier Concentration

Supplier concentration can be measured using indicators such as:

A. Market shares

The percentage of total sales attributable to each supplier.

For example:

The first two suppliers collectively account for 75% of the market.

B. Concentration ratio

The CR4 measures the combined market share of the four largest suppliers.

C. Herfindahl-Hirschman Index

The HHI is calculated by squaring each firm's market share and adding the results.

For the above example:

HHI = 45² + 30² + 15² + 10² = 3,250

A high HHI indicates a concentrated market, although the legal significance of a particular HHI depends on the jurisdiction and circumstances.

3. Relevant Laboratory Markets

A competition authority normally does not simply examine the entire "laboratory supply industry."

It may define narrower relevant markets such as:

• laboratory analytical instruments;
• chromatography instruments;
• mass spectrometry equipment;
• cell-culture products;
• tissue-culture vessels;
• diagnostic reagents;
• blood reagents;
• molecular-testing reagents;
• laboratory chemicals;
• clinical-diagnostic distribution;
• laboratory information systems;
• laboratory software;
• laboratory equipment maintenance;
• veterinary diagnostic testing products.

The narrower the relevant market, the more significant concentration may become.

The European Commission, for example, has examined laboratory-product distribution separately from clinical-diagnostics distribution and has recognized the importance of technical requirements, long-term contracts, exclusivity and after-sales support in certain laboratory markets.

4. Why Lab Supplier Concentration Creates Competition Concerns

A. Increased Pricing Power

Where only a few suppliers remain, each supplier may face less competitive pressure.

A concentrated supplier may therefore have greater ability to:

• increase prices;
• reduce discounts;
• impose minimum purchase requirements;
• charge higher maintenance fees;
• increase reagent prices;
• reduce service quality.

However, concentration alone does not establish that a supplier possesses market power.

B. Equipment–Consumable Lock-In

Laboratory equipment frequently interacts with proprietary consumables.

For example:

Instrument → Proprietary reagent → Software → Maintenance → Replacement parts

If the equipment supplier controls several stages, laboratories may find it difficult to switch.

This creates an important competition-law question:

Are laboratory customers genuinely able to switch to another supplier?

If switching requires replacing expensive equipment, retraining staff and obtaining new regulatory validation, the effective switching cost may be substantial.

5. Installed-Base Effects

An important feature of laboratory markets is the installed base.

Once a laboratory purchases a particular instrument, the supplier may gain recurring sales of:

• reagents;
• cartridges;
• test kits;
• calibration materials;
• software;
• spare parts;
• maintenance;
• upgrades.

Consequently, a merger may create competition concerns even where the initial equipment market appears competitive.

6. Barriers to Entry

Entry into laboratory supply markets may be difficult because new suppliers may need:

• scientific expertise;
• regulatory approvals;
• intellectual-property rights;
• validated manufacturing processes;
• distribution networks;
• quality-control systems;
• technical support personnel;
• reputation and reliability;
• compatibility with laboratory equipment;
• long-term customer relationships.

Therefore, a highly concentrated market with substantial entry barriers may generate stronger competition concerns than a market where new suppliers can enter rapidly.

7. Merger Control

Merger control is one of the most important areas concerning laboratory supplier concentration.

Authorities examine whether an acquisition will:

1. eliminate an important competitor;
2. substantially increase concentration;
3. remove close competitive rivalry;
4. increase unilateral pricing power;
5. facilitate coordination;
6. create vertical foreclosure;
7. increase control over essential inputs;
8. make switching more difficult.

8. Case Law

1. Agilent Technologies / Varian — European Commission

Case COMP/M.5611, Agilent/Varian (2010)

Agilent proposed acquiring Varian, both active in bio-analytical measurement products and related laboratory instruments, consumables and software.

The European Commission's investigation found that Agilent and Varian were particularly close competitors in laboratory gas chromatography instruments. Customers considered the two products comparable and the companies frequently competed against each other in tenders.

Legal significance

The case demonstrates that competition authorities examine:

• actual competitive closeness;
• tender participation;
• customer substitution;
• product functionality;
• competitive alternatives;

rather than relying exclusively on aggregate industry concentration.

Principle

Eliminating a particularly close competitor can create competition concerns even where other suppliers remain.

2. Roche Holding / Corange — FTC

The FTC's investigation of Roche's acquisition of Corange considered several healthcare and laboratory-related markets.

In the market for DAT reagents used in workplace testing, Roche and Corange were two of only four suppliers. The FTC described the market as highly concentrated and identified a substantial increase in HHI following the proposed transaction.

Legal significance

The case illustrates how authorities can combine:

• market shares;
• HHI;
• number of suppliers;
• closeness of competition; and
• barriers to entry

to assess the competitive effects of a laboratory-reagent merger.

Principle

Concentration becomes particularly significant where a merger removes one of a small number of meaningful suppliers.

3. Thermo Fisher Scientific / Life Technologies — FTC

The FTC challenged aspects of Thermo Fisher's proposed acquisition of Life Technologies.

The transaction raised concerns concerning siRNA reagents, cell-culture media and cell-culture sera. According to the FTC, the original transaction would eliminate important competition and could permit increased prices or reduced quality. The parties ultimately agreed to divest assets to address the concerns.

Legal significance

This is especially important for laboratory supplier concentration because it demonstrates that competition authorities may scrutinize concentration at the level of specific laboratory inputs, rather than treating all scientific products as one market.

Principle

Product-specific concentration can be more important than the size of the parties in the overall laboratory industry.

4. Corning / Becton, Dickinson Discovery Labware — FTC

FTC, 2012

Corning proposed acquiring Becton, Dickinson's Discovery Labware business.

The FTC found that the relevant North American markets for tissue-culture-treated cell-culture products were highly concentrated. Corning and Discovery Labware were the leading suppliers, while other suppliers were considerably smaller.

The FTC was concerned that the transaction would eliminate direct competition between two important suppliers.

The settlement required Corning to provide products and assistance to Sigma-Aldrich so that Sigma-Aldrich could develop competing manufacturing capacity.

Legal significance

The remedy is particularly relevant to supplier concentration.

Rather than merely imposing behavioral restrictions, the remedy sought to restore an independent source of supply.

Principle

Where a merger removes a significant laboratory supplier, divestiture or supply arrangements may be used to preserve competition.

5. IDEXX Laboratories — FTC

FTC, 2012

IDEXX was the largest supplier of point-of-care diagnostic testing products for small-animal veterinarians.

The FTC alleged that IDEXX used exclusive distribution arrangements to prevent major distributors from carrying competing diagnostic products. The FTC stated that IDEXX had at least 70% of the relevant market during the relevant period.

IDEXX agreed to terminate the challenged exclusivity arrangements.

Legal significance

This case demonstrates that supplier concentration is not merely a merger issue.

A highly concentrated supplier may also face scrutiny when it uses exclusive distribution to prevent rivals from obtaining effective access to distributors.

Principle

A dominant laboratory supplier cannot necessarily use contractual exclusivity to reinforce its market position by foreclosing competing suppliers.

6. Nobel Scientific Industries v. Beckman Instruments

670 F. Supp. 1313 (D. Md. 1986)

The dispute concerned laboratory analyzers and reagents.

The plaintiff argued that a separate market existed for reagents associated with Beckman analyzers. The court rejected an excessively narrow market definition, finding that reagents for other analyzers could be reasonably interchangeable and therefore relevant to the competitive analysis.

Legal significance

The case demonstrates the importance of market definition in laboratory-supplier disputes.

A supplier may appear dominant if the market is defined as:

"reagents compatible with Supplier X's equipment"

but considerably less dominant if the market is:

"reagents usable with competing laboratory analyzers."

Principle

Compatibility and substitutability must be examined carefully before concluding that laboratory supplier concentration creates market power.

7. In re Blood Reagents Antitrust Litigation

266 F. Supp. 3d 750 (E.D. Pa. 2017)

The litigation concerned traditional blood reagents supplied by major producers Ortho-Clinical Diagnostics and Immucor.

Purchasers alleged that the two leading producers had engaged in conduct restraining competition and alleged substantial increases in blood-reagent prices. The litigation illustrates the antitrust risks associated with highly concentrated reagent markets.

Legal significance

A market with only a few major suppliers can create opportunities for:

• coordination;
• information exchange;
• parallel conduct;
• exclusionary conduct;
• price-related disputes.

Principle

Concentrated reagent markets require particular attention to coordinated conduct and evidence of actual competitive effects.

8. DM Research v. College of American Pathologists

170 F.3d 53 (1st Cir. 1999)

The case concerned the market for high-grade reagent water and related laboratory equipment.

The plaintiff alleged that professional standards and their implementation restricted competition and harmed its ability to sell reagent-water products. The First Circuit considered the alleged restraint under Section 1 of the Sherman Act.

Legal significance

The case illustrates that competition problems in laboratory supply markets can arise not only from mergers but also from:

• industry standards;
• professional organizations;
• certification systems;
• exclusionary standards;
• restrictions affecting market access.

Principle

Standards and professional requirements may have competition implications when they materially exclude competing laboratory suppliers.

9. Indian Competition-Law Perspective

In India, laboratory supplier concentration may be examined primarily under the Competition Act, 2002.

Three provisions are especially relevant.

Section 3

Section 3 addresses agreements causing or likely to cause an appreciable adverse effect on competition.

Potential laboratory-supply examples include:

• supplier cartels;
• bid rigging;
• market allocation;
• exclusive supply arrangements;
• resale restrictions;
• coordinated procurement arrangements.

Section 4

Section 4 concerns abuse of dominant position.

A dominant laboratory supplier could potentially face scrutiny for:

• unfair or discriminatory pricing;
• discriminatory conditions;
• denial of market access;
• tying;
• leveraging dominance into adjacent laboratory markets;
• exclusionary contractual practices.

Sections 5 and 6

These provisions concern combinations and merger control.

A laboratory-supply acquisition may therefore be examined where it substantially changes competitive conditions in a relevant market.

10. Star Imaging & Path Lab v. Siemens

CCI, Case No. 06 of 2020

This Indian case involved diagnostic laboratories purchasing imaging equipment from Siemens. The informants alleged, among other things, violations of Sections 3(4) and 4 concerning Siemens and its healthcare businesses.

The matter demonstrates the importance of examining the relationship between:

equipment supplier → diagnostic laboratory → after-sales services → consumables/technical ecosystem.

Principle

Laboratory-equipment markets must be analysed with attention to the commercial dependence created by installed equipment and associated services.

11. GE Healthcare / Thermo Fisher-related Combination

Indian merger-control practice has also examined transactions involving laboratory equipment and consumables.

In a 2014 CCI combination involving GE Healthcare Life Sciences and a Thermo Fisher-related divestment business, the CCI record described Thermo Fisher as active in analytical instruments and laboratory consumables, including reagents, across experimental-science applications.

Significance

The case illustrates the importance of examining:

• laboratory instruments;
• reagents;
• consumables;
• overlaps;
• vertical relationships;
• divestiture assets.

12. Key Competition Concerns

13. Vertical Concentration

Supplier concentration becomes more complicated when a laboratory company operates at several levels of the supply chain.

For example:

Manufacturer
↓
Distributor
↓
Laboratory
↓
Hospital / Diagnostic Centre
↓
Patient

If the manufacturer also owns the distributor, it may have an incentive to disadvantage rival manufacturers.

Potential practices include:

• discriminatory distribution;
• refusal to supply;
• preferential rebates;
• exclusive distribution;
• margin squeezing;
• tying;
• bundling;
• discriminatory technical support.

14. Equipment–Reagent Competition

This is one of the most important issues in laboratory competition law.

Suppose:

Company A sells an analyzer and requires its customers to purchase Company A's reagents.

If Company A possesses substantial market power, competition authorities may examine whether this arrangement prevents reagent suppliers from competing.

The analysis should consider:

1. Whether the analyzer is indispensable;
2. Whether compatible alternative reagents exist;
3. Whether customers can switch analyzers;
4. Whether switching costs are significant;
5. Whether alternative equipment is available;
6. Whether the restriction is technically justified;
7. Whether competitors are foreclosed.

15. Concentration and Public Procurement

Laboratory equipment and reagents are frequently purchased through:

• government hospitals;
• universities;
• research institutions;
• public laboratories;
• tenders;
• framework contracts.

A concentrated supplier market can create risks of:

Bid rigging

Competitors coordinate tender submissions.

Bid rotation

Suppliers take turns winning contracts.

Market allocation

Suppliers divide geographical or institutional customers.

Cover bidding

A competitor submits a deliberately unattractive bid.

Information exchange

Competitors exchange sensitive information concerning:

• prices;
• future bids;
• capacity;
• customers;
• discounts.

Such conduct can create liability independently of whether the market is structurally concentrated.

16. Economic Effects

Supplier concentration may produce both negative and potentially beneficial effects.

Potential competition concerns

• higher prices;
• reduced innovation;
• reduced product variety;
• weaker service quality;
• higher switching costs;
• greater dependence on one supplier;
• reduced bargaining power of laboratories.

Possible efficiencies

A larger laboratory supplier may also obtain:

• economies of scale;
• improved R&D capacity;
• wider distribution;
• better quality control;
• greater manufacturing efficiency;
• more extensive technical support;
• faster innovation.

Therefore, competition analysis must distinguish mere concentration from an actual or likely substantial lessening of competition or abuse of market power.

17. How Authorities Analyze Lab Supplier Concentration

A structured analysis generally proceeds as follows:

Step 1 — Define the relevant product market

Is the market:

• all laboratory equipment?
• particular instruments?
• particular reagents?
• clinical diagnostics?
• a specific consumable?

Step 2 — Define geographic scope

Determine whether competition is:

• local;
• national;
• regional;
• global.

Step 3 — Calculate market shares

Identify the shares of each supplier.

Step 4 — Examine concentration

Use:

• CR4;
• HHI;
• number of significant suppliers.

Step 5 — Identify competitive closeness

Determine whether the merging firms are particularly close substitutes.

Step 6 — Examine customer switching

Consider:

• equipment replacement;
• validation;
• staff training;
• regulatory requirements;
• compatibility.

Step 7 — Examine entry

Can a new supplier enter quickly and economically?

Step 8 — Examine vertical effects

Consider:

• distribution;
• consumables;
• software;
• maintenance;
• technical support.

Step 9 — Examine exclusionary conduct

Consider:

• exclusivity;
• tying;
• bundling;
• discriminatory access;
• refusal to deal.

Step 10 — Examine efficiencies

Assess whether claimed efficiencies are:

• verifiable;
• merger-specific;
• likely to benefit customers.

18. Remedies

Where laboratory supplier concentration raises competition concerns, authorities may consider:

Structural remedies

• divestiture of laboratory-product businesses;
• sale of manufacturing facilities;
• transfer of intellectual property;
• transfer of customer contracts;
• licensing of technology.

Behavioral remedies

• supply obligations;
• interoperability commitments;
• prohibition of exclusive dealing;
• non-discrimination requirements;
• access obligations;
• restrictions on tying.

The Corning/Discovery Labware matter illustrates a remedy aimed at creating an alternative supplier by transferring assets and supplying products to Sigma-Aldrich.

19. Important Legal Principles from the Cases

The cases collectively establish several important principles:

1. Concentration alone is not automatically unlawful.
2. Market definition is fundamental.
3. Close competition between two suppliers can make a merger problematic.
4. Laboratory reagents can constitute distinct relevant markets.
5. Installed-base effects can increase supplier power.
6. Exclusive distribution can reinforce an already strong position.
7. Equipment compatibility can affect market definition and switching.
8. Professional standards can potentially create exclusionary effects.
9. Divestiture may be necessary where concentration eliminates an important competitor.
10. The competitive assessment should focus on actual market effects rather than market-share figures alone.

20. Conclusion

Lab supplier concentration is a significant competition-law issue because laboratory markets often combine high concentration with switching costs, proprietary technologies, regulatory barriers, technical compatibility and recurring consumable purchases.

The principal legal question is not simply:

"How many laboratory suppliers exist?"

It is:

Whether the structure or conduct of the market gives suppliers the ability or incentive to reduce effective competition.

The Agilent/Varian, Roche/Corange, Thermo Fisher/Life Technologies, Corning/Discovery Labware, IDEXX, Nobel Scientific, Blood Reagents Antitrust Litigation, and DM Research matters collectively demonstrate how competition authorities and courts approach concentration through market definition, market shares, closeness of competition, entry barriers, switching costs, vertical foreclosure, exclusivity and actual competitive effects.

Exam takeaway: In laboratory markets, high supplier concentration becomes legally significant when it is accompanied by market power, substantial entry or switching barriers, elimination of close competitors, or exclusionary/coordination practices that materially restrict competition.